

Iain M. Cockburn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8154928/publications.pdf>

Version: 2024-02-01

41
papers

8,458
citations

186209

28
h-index

330025

37
g-index

60
all docs

60
docs citations

60
times ranked

4647
citing authors

#	ARTICLE	IF	CITATIONS
1	Measuring Competence? Exploring Firm Effects in Pharmaceutical Research. <i>Strategic Management Journal</i> , 1994, 15, 63-84.	4.7	2,049
2	Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery. <i>RAND Journal of Economics</i> , 1996, 27, 32.	1.3	898
3	Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery. <i>Journal of Industrial Economics</i> , 1998, 46, 157-182.	0.6	797
4	Gone but not forgotten: knowledge flows, labor mobility, and enduring social relationships. <i>Journal of Economic Geography</i> , 2006, 6, 571-591.	1.6	500
5	Untangling the origins of competitive advantage. <i>Strategic Management Journal</i> , 2000, 21, 1123-1145.	4.7	376
6	The anchor tenant hypothesis: exploring the role of large, local, R&D-intensive firms in regional innovation systems. <i>International Journal of Industrial Organization</i> , 2003, 21, 1227-1253.	0.6	304
7	Information Technology and Intangible Output: The Impact of IT Investment on Innovation Productivity. <i>Information Systems Research</i> , 2012, 23, 42-59.	2.2	301
8	Opportunity costs and entrepreneurial activity. <i>Journal of Business Venturing</i> , 1995, 10, 95-106.	4.0	256
9	The Changing Structure Of The Pharmaceutical Industry. <i>Health Affairs</i> , 2004, 23, 10-22.	2.5	195
10	Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research. <i>Journal of Health Economics</i> , 2001, 20, 1033-1057.	1.3	172
11	Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins. <i>RAND Journal of Economics</i> , 1997, 28, 426.	1.3	167
12	Mixed Poisson Regression Models with Covariate Dependent Rates. <i>Biometrics</i> , 1996, 52, 381.	0.8	151
13	<scp>Patents, Thickets and the Financing of Early-Stage Firms: Evidence from the Software Industry</scp>. <i>Journal of Economics and Management Strategy</i> , 2009, 18, 729-773.	0.4	121
14	Entry and Patenting in the Software Industry. <i>Management Science</i> , 2011, 57, 915-933.	2.4	118
15	Loss of Work Productivity due to Illness and Medical Treatment. <i>Journal of Occupational and Environmental Medicine</i> , 1999, 41, 948-953.	0.9	117
16	Patents and the survival of Internet-related IPOs. <i>Research Policy</i> , 2010, 39, 214-228.	3.3	113
17	Why are some regions more innovative than others? The role of small firms in the presence of large labs. <i>Journal of Urban Economics</i> , 2014, 81, 149-165.	2.4	113
18	Public-private interaction in pharmaceutical research. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 12725-12730.	3.3	105

#	ARTICLE	IF	CITATIONS
19	Patents and the Global Diffusion of New Drugs. <i>American Economic Review</i> , 2016, 106, 136-164.	4.0	102
20	New Pills for Poor People? Empirical Evidence after GATT. <i>World Development</i> , 2001, 29, 265-289.	2.6	100
21	Not Invented Here? Innovation in company towns. <i>Journal of Urban Economics</i> , 2010, 67, 78-89.	2.4	90
22	Impact of Clinical Trial Results on National Trends in β -Blocker Prescribing, 1996-2002. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 54.	3.8	84
23	DO FIRMS CHANGE CAPABILITIES BY HIRING NEW PEOPLE? A STUDY OF THE ADOPTION OF SCIENCE-BASED DRUG DISCOVERY. <i>Advances in Strategic Management</i> , 0, , 133-159.	0.1	81
24	National trends in asthma visits and asthma pharmacotherapy, 1978-2002. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 111, 729-735.	1.5	70
25	The Market For Follow-On Biologics: How Will It Evolve?. <i>Health Affairs</i> , 2006, 25, 1291-1301.	2.5	69
26	Patent thickets, licensing and innovative performance. <i>Industrial and Corporate Change</i> , 2010, 19, 899-925.	1.7	67
27	A statistical analysis of the magnitude and composition of drug promotion in the United States in 1998. <i>Clinical Therapeutics</i> , 2003, 25, 1503-1517.	1.1	61
28	The Impact of Incremental Innovation in Biopharmaceuticals. <i>Pharmacoeconomics</i> , 2006, 24, 69-86.	1.7	42
29	Analysis of Patent Data: A Mixed-Poisson-Regression-Model Approach. <i>Journal of Business and Economic Statistics</i> , 1998, 16, 27.	1.8	33
30	Deals not done: Sources of failure in the market for ideas. <i>Strategic Management Journal</i> , 2015, 36, 976-986.	4.7	33
31	Faster, smaller, cheaper: an hedonic price analysis of PDAs. <i>Applied Economics</i> , 2008, 40, 2839-2856.	1.2	32
32	The Hidden Cost Of Low Prices: Limited Access To New Drugs In India. <i>Health Affairs</i> , 2014, 33, 1567-1575.	2.5	31
33	Bridging the gap: improving clinical development and the regulatory pathways for health products for neglected diseases. <i>Clinical Trials</i> , 2010, 7, 719-734.	0.7	28
34	Finding the Endless Frontier: Lessons from the Life Sciences Innovation System for Technology Policy. <i>Capitalism and Society</i> , 2010, 5, .	0.3	19
35	Hedonic Analysis of Arthritis Drugs. , 0, , 439-458.		15
36	Access to intellectual property for innovation: Evidence on problems and coping strategies from German firms. <i>Research Policy</i> , 2013, 42, 529-541.	3.3	14

#	ARTICLE	IF	CITATIONS
37	Patent Thickets, Licensing and Innovative Performance. SSRN Electronic Journal, 0, , .	0.4	10
38	Diffusion of New Drugs in the Post-TRIPS Era. International Journal of the Economics of Business, 2011, 18, 203-224.	1.0	8
39	Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine. Clinical Therapeutics, 1999, 21, 917-924.	1.1	4
40	O Brave New Industry, That Has Such Patents in It! Reflections on the Economic Consequences of Patenting DNA. Advances in Genetics, 2003, 50, 385-398.	0.8	4
41	National Bureau of Economic Research Patent Database: Audio of Presentation. SSRN Electronic Journal, 0, , .	0.4	0